Tempus AI will acquire Personalis in a $1.5 billion all-stock deal, expanding its cancer recurrence monitoring capabilities. Personalis shareholders will receive $16.25 per share, a premium of 6% over the recent closing price. The acquisition builds on a 2023 partnership and aims to leverage Personalis' technology that tracks circulating tumor DNA, which has Medicare coverage for three indications. The deal is expected to close by early 2027, pending approvals.
Personalis, a cancer testing firm, is being acquired by Tempus AI in a $1.5 billion all-stock deal offering $16.25 per share, a 28% premium. Despite the premium, Personalis shares dropped 13.39% on the announcement day due to capped upside until deal...
Julie & Holleman LLP is investigating whether Personalis shareholders are receiving fair value in Tempus AI's proposed acquisition at $16.25 per share. Tempus, already a significant shareholder and strategic partner since 2023, may have conflicts of ...
